Inflammation Research Association Proceedings of the Seventh International Conference Editorial Pages: S113 - S113
Intra-articular injection of stromelysin into rabbit knees as a model to evaluate matrix metalloprotease inhibitors R. L. GoldbergD. ParkerE. O'Byrne I. Cartilage degradation and osteoarthritis Pages: S115 - S116
Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits E. M. O'ByrneD. T. ParkerV. S. Ganu I. Cartilage degradation and osteoarthritis Pages: S117 - S118
Stromelysin expression in IL-1β stimulated bovine articular cartilage explants S. WertheimerS. KatzA. C. Hanglow I. Cartilage degradation and osteoarthritis Pages: S119 - S120
Molecular cloning and characterization of rabbit TIMP2 S. J. WertheimerS. L. Katz I. Cartilage degradation and osteoarthritis Pages: S121 - S122
Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats M. DiMartinoC. WolffP. Nambi I. Cartilage degradation and osteoarthritis Pages: S123 - S124
The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice P. H. WooleyJ. D. WhalenD. F. Counts I. Cartilage degradation and osteoarthritis Pages: S125 - S126
Overexpression of the NC4 domain of type IX collagen induces osteoarthritis in mice H. B. HaimesP. A. JimenezB. R. Olsen I. Cartilage degradation and osteoarthritis Pages: S127 - S128
Induction of osteoarthritis in guinea pigs by transection of the anterior cruciate ligament: Radiographic and histopathological changes P. A. JimenezP. M. HarlanH. B. Haimes I. Cartilage degradation and osteoarthritis Pages: S129 - S130
Metalloprotease inhibitors halt collagen breakdown in IL-1 induced bovine nasal cartilage cultures S. SpiritoJ. DoughtyR. L. Goldberg I. Cartilage degradation and osteoarthritis Pages: S131 - S132
Antinociceptive activities of non-steroidal antiinflammatory drugs (NSAIDs) following intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration in mice T. L. WalterT. T. Chau II. Lipid mediators Pages: S133 - S134
Identification and partial characterization of an acidic sphingomyelinase (SMase) from cultured human umbilical vein endothelial cells (HUVEC) J. F. TruaxF. R. Cochran II. Lipid mediators Pages: S135 - S136
3(S)-hydroxy-leukotriene B4 is a potent granulocyte chemotaxin in the guinea pig dermis D. FretlandC. AnglinJ. Falck II. Lipid mediators Pages: S137 - S138
Differential involvement of protein kinase C in activating cytosolic phospholipase A2 in alveolar macrophages and monocyte differentiated U937 cells M. T. WithnallA. M. PenningtonM. Hagen II. Lipid mediators Pages: S139 - S140
Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models A. RaychaudhuriB. KotyukA. J. Main II. Lipid mediators Pages: S141 - S142
The pharmacokinetics and metabolism of SC-53228, a specific leukotriene B4 receptor antagonist S. PaulsonY. ReadusD. Fretland II. Lipid mediators Pages: S143 - S144
A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2) R. HuffP. CollinsP. Isakson II. Lipid mediators Pages: S145 - S146
CGS 26529: The biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action E. KimbleT. KowalskiJ. van Duzer II. Lipid mediators Pages: S147 - S148
Role of induced nitric oxide synthase and increased NO levels in zymosan peritonitis in the rat N. K. Boughton-SmithA. Ghelani III. Nitric Oxide Pages: S149 - S150
Degradation of bovine cartilage proteoglycanin vitro is enhanced by inhibition of nitric oxide synthase A. C. HanglowK. RowanJ. W. Coffey III. Nitric Oxide Pages: S151 - S152
Role of inducible nitric oxide synthase (iNOS) and peroxynitrite in gut inflammation N. D. SeagoD. A. ClarkM. J. S. Miller III. Nitric Oxide Pages: S153 - S154
Flow cytometric assessment of NADPH oxidase inhibitors in whole blood W. HastonJ. H. van DuzerJ. C. Quintavalla III. Nitric Oxide Pages: S155 - S157
Activation of blood complement in guinea pigs receiving an intravenous injection of Sephadex beads J. -F. BlainK. MaghniP. Sirois IV. New animal models of inflammatory diseases Pages: S158 - S159
Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone H. TowbinW. PignatI. Wiesenberg IV. New animal models of inflammatory diseases Pages: S160 - S161
A novel contact hypersensitivity model for rank-ordering formulated corticosteroids S. C. BaileyF. AsgharE. S. Kurtz IV. New animal models of inflammatory diseases Pages: S162 - S163
Radiological assessment of relaxin-induced pubic symphyseal changes in guinea pigs: A model for screening disease modifying agents for osteoarthritis P. A. JimenezB. G. SteinetzH. B. Haimes IV. New animal models of inflammatory diseases Pages: S164 - S165
Granulocyte recruitment in guinea pig lungs following the administration of MBP-like cationic protein D. ArseneaultK. MaghniP. Sirois V. Pulmonary inflammation Pages: S166 - S167
Specific increase of microvascular permeability in lower airways of guinea pigs injected with Sephadex beads S. Y. MartineauK. MaghniP. Sirois V. Pulmonary inflammation Pages: S168 - S169
Pulmonary pharmacology of WAY-126299A: A dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist R. E. HowellL. P. JenkinsD. Grimes V. Pulmonary inflammation Pages: S170 - S171
Pulmonary antiallergic and antiinflammatory effects of a novel, orallyactive phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats R. E. HowellS. L. WoeppelR. J. Heaslip V. Pulmonary inflammation Pages: S172 - S173
Relationship between the development of bronchial hyperresponsiveness and the airway eosinophilia in guinea pigs following injection with Sephadex beads K. MaghniM. J. SimardP. Sirois V. Pulmonary inflammation Pages: S174 - S176
Differential modulation by betamethasone of allergen-induced cell influx and cell peroxidase in guinea-pig lungs M. YeadonA. A. PetrovicA. N. Payne V. Pulmonary inflammation Pages: S177 - S178
Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes C. C. BansbachD. WancioS. N. Sehgal VI. Lymphocyte activation/immunoregulation Pages: S179 - S180
The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor E. KimbleJ. HadalaP. Simon VI. Lymphocyte activation/immunoregulation Pages: S181 - S182
CP-123,369: A potent, orally active immunosuppressive agent K. KochD. C. HansonB. M. Meiser VI. Lymphocyte activation/immunoregulation Pages: S183 - S184
Interferon-γ and antibodies to interleukin-5 and interleukin-4 inhibit the pulmonary eosinophilia in allergic mice T. T. KungD. M. SteltsR. W. Chapman VI. Lymphocyte activation/immunoregulation Pages: S185 - S186
Leflunomide: An active antiinflammatory and antiproliferative agent in models of dermatologic disease E. S. KurtzS. C. BaileyP. A. Przekop VI. Lymphocyte activation/immunoregulation Pages: S187 - S188
Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation K. L. Molnar-KimberA. RhoadS. N. Sehgal VI. Lymphocyte activation/immunoregulation Pages: S189 - S190
Evaluation of lymphocyte subsets in tamarins and marmosets M. G. PetersenB. BeegleJ. E. Fuhr VI. Lymphocyte activation/immunoregulation Pages: S191 - S192
The modified recalcification time (MRT) test assesses suppressive effect of general anesthesia (GA) on monocyte function R. PonnuduraiH. RamasubramaniamE. J. Lazaro VI. Lymphocyte activation/immunoregulation Pages: S193 - S193
Modulation of the immunoglobulin dysregulation in GvH- and SLE-like diseases by the murine IL-4 receptor (IL-4-R) H. -U. SchorlemmerG. DickneiteK. -H. Enssle VI. Lymphocyte activation/immunoregulation Pages: S194 - S196
Endotoxin negates anticoagulant effect of cyclosporine C. R. SpillertS. BonthuE. J. Lazaro VI. Lymphocyte activation/immunoregulation Pages: S197 - S197
Heavy water activates monocyte generation of tissue factor C. R. SpillertR. N. GonzalesE. J. Lazaro VI. Lymphocyte activation/immunoregulation Pages: S198 - S198
Anti-inflammatory activity of an orally active peptide sequence from PF-4 on acute inflammation and DTH J. E. TalmadgeL. S. KelseyD. F. Counts VI. Lymphocyte activation/immunoregulation Pages: S199 - S200
Digoxin and endotoxin: A lethal pro-inflammatory combination D. S. TichanskyC. R. SpillertE. J. Lazaro VI. Lymphocyte activation/immunoregulation Pages: S201 - S201
Modified recalcification time (MRT): A model to assess drug-induced depressed immune function E. WamstekerC. R. SpillertE. J. Lazaro VI. Lymphocyte activation/immunoregulation Pages: S202 - S202
Pharmacological inhibition of CD28-stimulated T cell activation D. WancioN. K. DamleC. C. Bansbach VI. Lymphocyte activation/immunoregulation Pages: S203 - S204
Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse L. M. WarnerT. CummonsS. N. Sehgal VI. Lymphocyte activation/immunoregulation Pages: S205 - S206
Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? T. ZielinskiD. ZeitterR. R. Bartlett VI. Lymphocyte activation/immunoregulation Pages: S207 - S208
Ultraviolet B-induced inflammatory cytokine production,in vivo: Initial pharmacological characterization D. E. GriswoldM. N. Tzimas VII. Inflammatory cytokines Pages: S209 - S210